RARE
ULTRAGENYX PHARMACEUTICAL IN
Latest close $24.97 as of Aug 5, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 6 parsed filing(s) · 3 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Vanguard Capital Management CIK0002100119 | Jun 30, 2026 observed Jul 31, 2026 filed · 31d Initial Schedule 13G | Initial Schedule 13G | 5.1M | 12.00% | $33.39 | $24.91 | $24.97 |
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 30, 2026 filed · 30d Schedule 13G amendment | Earliest Schedule 13G amendment found | 8.1M | 12.00% | $33.39 | $26.04 | $24.97 |
| State Street CIK0000093751 | Mar 31, 2026 observed May 12, 2026 filed · 42d Initial Schedule 13G | Initial Schedule 13G | 5.0M | 12.00% | $20.95 | $26.84 | $24.97 |